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Limited studies have compared the impact of different antiretroviral regimens on soluble 
markers of inflammation with discordant results. In this prospective study, treatment naïve 
HIV-1-infected patients were included if they started their current regimen with 
atazanavir/ritonavir (ATV/r)(N= 73, Group 1) or darunavir/ritonavir (DRV/r) (N=85, Group 
2) plus tenofovir/emtricitabine. The analysis of IL-6, MCP-1, sCD163, VCAM-1, ox-LDL and 
adiponectine was performed on two stored plasma samples, the first prior to antiretroviral 
therapy initiation and the second one year after initiation. The results of our analysis show a 
difference in ox-LDL between the two groups with higher mean (SD) values in ATV/r based 
group 608.5 ± 137.4 vs 519.1 ± 119.6 in DRV/r group , after controlling for baseline levels of 
ox-LDL as well as other potential confounding factors controlled by means of matching design 
or linear regression modelling. Our analysis provides further data examining the association 
between the modulation of vascular inflammatory and of activation markers with specific 
protease inhibitors-based treatments over one year of exposure to these drugs. The data show 
little evidence for an association, supporting the notion that antiretroviral regimens has 
generally poor efficiency in downregulating these soluble markers.  
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Chronic immune activation and inflammation are a hallmark of human immunodeficiency 
virus (HIV) infection and represent a key component of HIV pathogenesis [1,2]. Such 
persistent immune activation has been shown to increase non-AIDS complications such as 
cardiovascular risk, loss of bone mineral density and neurocognitive disorders [3-7]. 
Antiretroviral therapy (ART) is able to induce the control of HIV replication, but immune 
activation persists in people living with HIV (PLWHIV) [8-11]. Limited studies have compared 
the impact of different ART on residual immune activation and soluble markers of 
inflammation with discordant results [12-19]. However, the effects of different ART on 
cellular or soluble markers of activation are unclear. 
With this analysis we aimed to compare changes in soluble biomarkers of vascular 
inflammation/activation and the impact of an increase in bilirubin level in patients who 
started tenofovir/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r) or 
darunavir/ritonavir (DRV/r) based as their first-line ART. In particular, some markers that 
have not been previously thoroughly investigated in the literature.  
 
 
Patients and methods 
In this prospective study, treatment naïve HIV-1-infected patients enrolled in the ICONA 
(Italian Cohort Naïve Antiretrovirals) Foundation Study cohort were included if they started 
their current regimen with ATV/r (Group 1) or DRV/r (Group 2) plus TDF/FTC. Participants 
also need to have two stored plasma samples, the first prior to ART initiation and the second 
one year after initiation (time window: +9; +15 months) to be included. Exclusion criteria 
were patients with HIV-2 infection and HCV-RNA. 
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Patients receiving ATV/r or DRV/r were matched by age (± 5 years), gender, mode of HIV 
transmission, race, T CD4+ absolute cell count (groups as ≤200, 201-350 and >350), and a 
CD4/CD8 ratio (grouped as ≤0.3, 0.4-0.7 and >0.7).  
 
Soluble markers 
From frozen plasma the concentrations of Interleukin-6 (IL-6) pg/ml, Monocyte 
Chemoattractant Protein-1 (MCP-1) pg/ml, soluble (s) CD163 pg/ml, Vascular Cell Adhesion 
Molecule- 1 (VCAM-1) pg/ml and adiponectin pg/ml were measured by a bead-based 
immunoassay (AimPlex Premixed Multiplex Kit Human Custom 4-Plex for IL-6, MCP-1, 
sCD163, VCAM-1 determinations, Co. AimPlex Assay Kit Human Adiponectin respectively, 
from YSL Bioprocess Development) according to the manufacturer’s instructions [20] using 
the FACS Canto II flow cytometer (Becton Dickinson, BD) equipped with the FACS DIVA 
version 6.0 software (BD). Plasma cytokine concentration was expressed in picograms per 
milliliter by FlowCytomix Pro Software (BD) [21]. Circulating plasma oxidized-low density 
lipoprotein (ox-LDL) measurements were performed by the enzyme-linked immunosorbent 
assay Mercodia Oxidized LDL ELISA, according to the manufacturer’s instructions (Mercodia 
AB). Plasma ox-LDL concentration was expressed in mU/L.  
 
Statistical analyses  
Patients’ characteristics were compared according to the type of third PI/r drug initiated 
(ATV/r vs. DRV/r) using Wilcoxon chi-square (for categorical variables) and nonparametric 
tests for comparison of median (for numeric variables). The 12-month biomarkers values 
were compared in the ATV/r vs. DRV/r recipient group by means of an analysis of covariance 
(ANCOVA) adjusted for baseline values. Markers were modelled on the 10-logarithmic scale to 
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satisfy the normal distribution assumption. The multivariable ANCOVA model included the 
following potentially confounding factors: age, sex, smoking, diabetes, HIV-RNA, and T CD4 
baseline counts. The model with ox-LDL as the response variable was further adjusted for 
baseline LDL cholesterol and for statin use. A 'sensitivity analysis' was also performed after 
restricting the regression analysis to patients who had maintained the same pair of NRTIs 
(TDF / FTC) for the entire 12-month period. 
Instead of removing the non-matched individuals we kept them in the analysis and performed 
an additional adjustment by including patients’ characteristics as covariate in the ANOVA 
model. A repeated-measures one-way analysis which correctly handles the matched structure 
of the data are used. 
 
Results 
We enrolled 73 patients (62 males, 85%) in Group 1 (ATV/r) and 85 patients (77 males, 90%) 
in Group 2 (DRV/r). At treatment initiation (baseline) the median (IQR) T CD4+ cell count was 
413 (281-589), and 332 (110-510) in Group 1 and 2, respectively (p=0.05). A statistically 
significant difference (p= 0.005) was found between two groups in the median (IQR) HIV-RNA 
log10 copies/ml, higher in the DRV/r group: 4.67 (4.06-5.26) and 5.17 (4.73-5.49), 
respectively. At the baseline no difference was found (p= 0.63) in average levels of total 
bilirubin 0.5 (0.41-0.72) and 0.53 (0.38-0.7), proportion with a history of cardiovascular 
diseases: 2 (2.4%) in group 1 and 4 (5.5%) in group 2 (p=0.31), and proportion with a history 
of hypertension: 9 (10.6%) vs. 5 (6.8%), respectively (p=0.41) (Table 1). At the second time-
point 132/158 (84%) patients had undetectable HIV-RNA load. During the study follow up 
only 17 patients modified the original NRTI-pair (6 of those who started ATV/r and 11 of 
those who started DRV/r). 
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Mean unadjusted biomarkers, CD4 count, HIV-RNA and bilirubin values are shown in Table 2. 
In this ANCOVA analysis (univariate and multivariate analysis for soluble biomarkers in the 
two groups), adjusted for age, gender, smoking, diabetes, HIV-RNA and T CD4+ cell count, 
plasma LDL and use of statins at baseline, we found that after 1 year of exposure to DRV/r or 
ATV/r-based regimens, ox-LDL were lower in the group of patients treated by DRV/r.  We did 
not found evidence for a difference between the two groups for any of the other soluble 
markers evaluated. 
We performed also a univariable sensitivity analysis of soluble biomarkers after restricting to 
patients who remained on TDF/FTC up to the date of collection of the second plasma sample. 
Again, only for ox-LDL, the association was statistically significant (p= 0.007) with higher 
values in ATV/r based group. No statistically significant differences were found for IL-6 (p= 
0.708), MCP-1 (p=0.864), sCD163 (p=0.977), sVCAM-1 (p= 0.257) and adiponectin (p= 0.389). 
 
Discussion 
The rationale for comparing biomarkers profiles in patients receiving ATV/r or DRV/r-based 
regimens was dictated by the fact that the possible impact of these specific PI drugs on levels 
of soluble markers of inflammation has not been previously thoroughly investigated. 
In the ATADAR Study no major differences between ATV/r and DRV/r in cholesterol fractions, 
over 96 weeks were observed, however, ATV/r led to higher triglycerides and more total and 
subcutaneous fat than DRV/r. Fat gains with ATV/r were associated with insulin resistance. In 
contrast with what occurred in the ATV/r arm, the LDL subfraction phenotype improved with 
DRV/r at week 48. This difference was associated with a lower impact on plasma triglycerides 
with DRV/r [22,23]. In a substudy of ATADAR, there was a trend for a faster Carotid-Intima 
media thickness progression in people treated with DRV/r as compared to those on ATV/r 
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[24]. In the D:A:D. Study, cumulative use of DRV/rtv, but not of ATV/rtv, was independently 
associated with a progressively increasing risk of centrally validated cardiovascular events 
[25]. In our study the only biomarker showing a difference between the studied anchor dugs 
was ox-LDL but only when restricting the analysis to patients who did not modify their NRTI-
pair over time, levels being lower in people who started DRV/r. The results for other 
biomarkers were similar in the intention to-treat and per-protocol analyses restricted to 
people remaining on TDF/FTC. Ox-LDL expresses an inflammatory vascular damage 
correlated also with activation of innate immunity subsets [11]. In the group of patients 
treated with DRV/r we found a reduction of level of this marker compared to other group of 
ATV/r treated patients. The levels of bilirubin, as well as the therapy with TDF/FTC, were not 
associated with the studied soluble markers, except for ox-LDL in the group with a stable 
backbone of antiretroviral therapy, with lower levels in DRV/r group of patients. 
Furthermore there was no evidence for an association between change in bilirubin over the 
study period and any of the changes in retrospectively measured biomarkers, except for 
adiponectine values (positively correlated). 
Our analysis has some limitations. First, this is not a randomized comparison and therefore 
we cannot rule out that results might be affected by unmeasured confounding. Second, it is a 
limited comparison restricted to two specific PI-based regimens with no comparison with 
other type of regimens frequently used in first line (INSTI-based) or in simplifications 
strategies (NRTI-sparing regimens). Moreover, we did not correlate the soluble markers with 
parameters of activation of innate and adaptive cellular immunity, that probably playing a 
leading role in the inflammation process [26]. 
In conclusion, our analysis provides further data examining the association between the 
modulation of vascular inflammatory and of activation markers with specific PI-based 
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treatments over one year of exposure to these drugs. The data show little evidence for an 
association, supporting the notion that ART has generally poor efficiency in downregulating 
these soluble markers [14-17]. In contrast, ox-LDL appeared to be elevated in people who 
received ATV/r as compared to DRV/r. Further analyses should be conducted to examine the 
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